Jim Simons Affimed N.V. Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.65 $196,483 - $277,640	-427,139 Reduced 72.45%	162,458 $78,000
Q2 2023 Aug 11, 2023	SELL	$0.57 - $1.08 $466,627 - $884,136	-818,645 Reduced 58.13%	589,597 $353,000
Q1 2023 May 12, 2023	BUY	$0.66 - $1.29 $430,535 - $841,501	652,327 Added 86.3%	1,408,242 $1.05 Million
Q4 2022 Feb 13, 2023	BUY	$1.1 - $2.45 $678,082 - $1.51 Million	616,439 Added 441.97%	755,915 $937,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.32 $298,892 - $506,286	-152,496 Reduced 52.23%	139,476 $287,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $662,776 - $1.42 Million	291,972 New	291,972 $809,000
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $960,846 - $1.3 Million	-173,438 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $264,286 - $387,258	-33,970 Reduced 16.38%	173,438 $1.47 Million
Q1 2021 May 13, 2021	SELL	$5.12 - $8.48 $2.26 Million - $3.75 Million	-441,741 Reduced 68.05%	207,408 $1.64 Million
Q4 2020 Feb 10, 2021	BUY	$3.16 - $7.03 $1.89 Million - $4.2 Million	597,549 Added 1158.04%	649,149 $3.78 Million
Q3 2020 Nov 13, 2020	SELL	$3.26 - $4.73 $1.23 Million - $1.79 Million	-378,000 Reduced 87.99%	51,600 $175,000
Q2 2020 Aug 13, 2020	BUY	$1.58 - $4.63 $75,208 - $220,388	47,600 Added 12.46%	429,600 $1.98 Million
Q1 2020 May 14, 2020	BUY	$1.44 - $3.02 $550,080 - $1.15 Million	382,000 New	382,000 $604,000
Q2 2019 Aug 12, 2019	SELL	$2.6 - $4.21 $228,540 - $370,059	-87,900 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$3.05 - $4.34 $118,419 - $168,504	38,826 Added 79.12%	87,900 $369,000
Q4 2018 Feb 13, 2019	BUY	$2.82 - $4.67 $138,388 - $229,175	49,074 New	49,074 $153,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account